Şunu mu demek istediniz:
"who opens" » "who spends" (Aramayı Genişlet), "who owns" (Aramayı Genişlet), "who pen" (Aramayı Genişlet), "whdo opens" (Aramayı Genişlet), "whao opens" (Aramayı Genişlet), "who openss" (Aramayı Genişlet)
"so open" » "do open" (Aramayı Genişlet), "ao open" (Aramayı Genişlet), "caso open" (Aramayı Genişlet), "sdo open" (Aramayı Genişlet), "sao open" (Aramayı Genişlet), "so opens" (Aramayı Genişlet)
"esmo open" » "esmdo open" (Aramayı Genişlet), "esmao open" (Aramayı Genişlet), "esmo opens" (Aramayı Genişlet), "esto open" (Aramayı Genişlet), "eso open" (Aramayı Genişlet), "ecmo open" (Aramayı Genişlet)
"o open" » "do open" (Aramayı Genişlet), "ao open" (Aramayı Genişlet), "o opens" (Aramayı Genişlet)
Gösterilen 1 - 20 sonuçlar arası kayıtlar. 1,030 sonuç. Aranan kelime '(((((("who opens") OR ("who opens"))) OR ("esmo open"))) OR ((("o open") OR ("so open"))))*', Sorgu süresi: 1.47s Sonuçları Daraltın
PS2-6: Who Opens Alerts to Physicians? (And Who Doesn’t?)
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

ESMO Open—Cancer Horizons and the future of oncology
CSCO joins ESMO Open—Cancer Horizons

ESMO Open: news in breast cancer 2019
ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

ESMO Open special series on new emerging targets in cancer immunotherapy
Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

One year of ESMO Open: Cancer Horizons—where are we going from here?
Plasmodesmata. A Not So Open-and-Shut Case

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]
Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]
A lei geral de proteção de dados e o open finance

Arama Araçları: RSS Beslemesi — Aramayı e-posta ile gönder — Aramayı sakla